Tarlox and Sotorasib in Patients With KRAS G12C Mutations
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase IB dose expansion trial with safety lead-in evaluating the safety, clinical
activity/efficacy of the combination of tarloxotinib and sotorasib in patients with KRAS G12C
mutation who have progressed on any small molecule targeting KRAS G12C mutant Non-Small Cell
lung cancer.